Fast acetylators can be identified through pharmacogenetic testing, which analyzes specific genetic markers associated with the NAT2 gene. These tests can determine the acetylation phenotype by identifying allelic variations that correspond to fast or slow acetylation. Such testing is particularly useful in clinical settings to customize drug regimens and minimize adverse drug reactions.
